- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Solid tumours harbouring neurotrophic receptor tyrosine kinase (NTRK) gene fusions
- Meeting Date: March 2022
- Public Summary Document (PSD) March 2022 PBAC Meeting - (PDF 1.6MB)
- Public Summary Document (PSD) March 2022 PBAC Meeting - (Word 564KB)
Larotrectinib – March 2022
Larotrectinib: Capsule 25 mg, Capsule 100 mg, Oral solution 20 mg per mL, 100 mL; Vitrakvi®
Last updated
1 July 2022